Carey OConnor Kolaja - 15 Jun 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Jun 2023
Net transactions value
-$25,300
Form type
4
Filing time
20 Jun 2023, 16:25:04 UTC
Previous filing
05 May 2023
Next filing
03 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Options Exercise $45,300 +2,500 +15% $18.12 19,061 15 Jun 2023 Direct
transaction RVNC Common Stock Sale $70,600 -2,500 -13% $28.24 16,561 15 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Stock Option (Right to buy) Options Exercise $0 -2,500 -23% $0.000000 8,256 15 Jun 2023 Common Stock 2,500 $18.12 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated March 16, 2023 by Ms. Kolaja.
F2 The shares subject to the stock option vested on May 4, 2023.